Sitafit 50 mg Tablet is an oral antidiabetic medicine belonging to the DPP-4 inhibitor class, widely used in the management of type 2 diabetes mellitus. It helps improve glycemic control by enhancing the body’s natural incretin system, which regulates insulin release and reduces excess glucagon secretion in a glucose-dependent manner. This leads to better control of blood sugar levels throughout the day. Sitafit is commonly used as part of a comprehensive treatment plan alongside diet and exercise, and may be prescribed alone or in combination therapy when single agents are insufficient. It is particularly suitable for patients requiring effective blood glucose management with a low risk of hypoglycemia, supporting long-term metabolic control and improved diabetes outcomes.